Kristen Landon - 26 Sep 2024 Form 4 Insider Report for 60 DEGREES PHARMACEUTICALS, INC. (SXTP)

Reporting relationship: Chief Operating Officer
Issuer ticker: SXTP
Reported as of: 26 Sep 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2025, 21:24:37 UTC
Prior SEC filing: 14 Aug 2025
Next SEC filing: 14 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Kristen Landon

Key filing fact

Kristen Landon filed Form 4 for 60 DEGREES PHARMACEUTICALS, INC. (SXTP) on 14 Aug 2025.

Key facts

This page summarizes Kristen Landon's Form 4 filing for 60 DEGREES PHARMACEUTICALS, INC. (SXTP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Aug 2025, 21:24.

Change

Previous filing in this sequence was filed on 14 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002053910 Primary reporting owner

Landon Kristen

Relationship: Chief Operating Officer
Address: C/O 60 DEGREES PHARMACEUTICALS, INC., 1025 CONNECTICUT AVENUE NW SUITE 1000, WASHINGTON
Signature: /s/ Kristen Landon
Signature date: 14 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SXTP transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +4,167
Change %
Price: $0.000000
Shares after: 4,167
Date: 26 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,167
Exercise price: $6.85
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The options were granted pursuant to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The options shall vest and become exercisable in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024. The options have a maximum term of 10 years from the date of grant.

Footnote F2

This Form 4 is being filed late due to an inadvertent administrative error.

Footnote F3

All information has been retroactively adjusted to reflect the 1-for-5 reverse stock split effected by the Issuer on February 24, 2025.